NCT00493220 - Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Healthy

Interventions

DRUG

SC HYLENEX and Ceftriaxone

single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)

DRUG

SC Placebo and Ceftriaxone

single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)

DRUG

IV Ceftriaxone

single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)